Print
Email
Print Edition StoriesTuesday, April 22, 2008
GlaxoSmithKline to buy Sirtris for $720M
British drug giant GlaxoSmithKline PLC has agreed to acquire Sirtris Pharmaceuticals Inc. of Cambridge for $720 million.
Glaxo said it would keep Sirtris (NASDAQ: SIRT) as an autonomous unit of its drug discovery business and plans to retain Sirtris CEO Christoph Westphal and the rest of the company's employees. The British pharmaceutical firm (NYSE: GSK) plans to begin a tender offer of $22.50 per share of Sirtris common stock in May and close the deal in the second quarter of 2007. Sirtris's stock closed at $12.23 per share Tuesday.
Sirtris has gained wide recognition for its experimental, anti-aging treatments. The firm has a pipeline of small-molecule drugs that target genes linked to enzymes called sirtuins that are believe to have anti-aging effects and could be used to treat diabetes, cancer and other major diseases.
With 57 employees, the biotech firm reported a 2007 net loss of $31.1 million and no revenue. Glaxo said it would maintain Sirtris' operations in Cambridge.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
